Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1385&sort=-title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1386&sort=-title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-title" }, "data": [ { "type": "Grant", "id": "7950", "attributes": { "award_id": "1R21CA261775-01A1", "title": "A Practical Approach to Tumor-Specific Aptamers for B-Cell Hematologic Malignancies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23826, "first_name": "Tawnya C", "last_name": "Mckee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-05-01", "end_date": "2025-04-30", "award_amount": 191869, "principal_investigator": { "id": 23827, "first_name": "Qiao", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 922, "ror": "", "name": "COLUMBIA UNIV NEW YORK MORNINGSIDE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 922, "ror": "", "name": "COLUMBIA UNIV NEW YORK MORNINGSIDE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Personalized medicine will greatly improve the effectiveness of cancer care; however, the development of practically attainable patient-specific strategies has remained challenging. One unique opportunity exists with B cell-derived malignancies, which often express surface immunoglobulins (sIgs) with variable regions (idiotypes, Ids) within their B-cell receptors (BCRs). As malignant cells originate from a single clone, such sIg-Id molecules are specific to the tumor and unique to each patient. Targeting sIg-Ids can hence enable personalized disease identification and treatment strategies. Early studies using patient-specific anti-sIg-Id antibodies yielded promising results but were deemed unsustainable. A technology to generate personalized ligands in a time- efficient and cost-effective manner remains an unmet need in sIg-Id-based diagnostics and therapeutics. Aptamers, i.e., single-stranded oligonucleotides that specifically bind to biological targets, offer an attractive solution to this unmet need. Aptamers are isolated from a randomized oligonucleotide library via an in vitro process known as SELEX, which is traditionally labor-intensive, time-consuming (up to a month), and impractical for personalized aptamer generation. In contrast, we have developed a microfluidic platform, called microSELEX (μSELEX), which has been used to isolate aptamers for protein biomarkers, including Id regions of monoclonal antibodies from patients with multiple myeloma and COVID-19. Given a monoclonal protein from a patient sample, the platform is capable of rapidly isolating personalized anti-Id aptamers within ~10 hours. We propose to explore time-efficient and cost-effective μSELEX isolation of patient-specific DNA aptamers targeting sIg-Ids of tumor B cells for B-cell hematologic malignancies. We will first establish an optimal μSELEX protocol using B cell-derived cell lines, then isolate anti-sIg aptamers against tumor B cells obtained from peripheral blood samples of B cell lymphoma patients, and finally demonstrate noninvasive peripheral blood- based monitoring of minimal residual disease by using the aptamers to detect circulating tumor B cells. In addition to enabling timely identification of minimal residual disease for more precise clinical decision making, anti-sIg-Id aptamers can also be used as therapeutic ligands to enable personalized and precisely targeted therapy for more effective disease treatment. Such personalized aptamers can hence potentially lead to transformative changes in the care of patients with B-cell hematologic malignancies.", "keywords": [ "Affinity", "Antibodies", "B lymphoid malignancy", "B-Cell Antigen Receptor", "B-Cell Lymphomas", "B-Cell Neoplasm", "B-Lymphocytes", "Behavior", "Binding", "Biochemical", "Biological", "Blood specimen", "COVID-19", "Cancer Diagnostics", "Cell Line", "Cell surface", "Cells", "Chronic Lymphocytic Leukemia", "Classification", "Clinical", "Consumption", "DNA", "Detection", "Development", "Devices", "Diagnostic", "Disease", "Disease remission", "Effectiveness", "Evolution", "Generations", "Hematologic Neoplasms", "Hour", "Immunoglobulin Idiotypes", "Immunoglobulins", "In Vitro", "Ions", "Lead", "Libraries", "Ligands", "Magic", "Magnetic nanoparticles", "Malignant - descriptor", "Malignant Neoplasms", "Mantle Cell Lymphoma", "Medicine", "Methods", "Microfluidics", "Monitor", "Monoclonal Antibodies", "Multiple Myeloma", "Nucleic Acids", "Oligonucleotides", "Pathologic", "Patient Care", "Patient Isolation", "Patients", "Precision therapeutics", "Process", "Proteins", "Protocols documentation", "Randomized", "Reagent", "Residual Neoplasm", "Residual Tumors", "Residual state", "Sampling", "Specificity", "Surface Immunoglobulins", "Tars", "Technology", "Therapeutic", "Time", "Tin", "Translations", "aptamer", "base", "cancer care", "cancer cell", "clinical decision-making", "cohort", "cost effective", "cross reactivity", "improved", "innovation", "nanoparticle", "neoplastic cell", "novel", "peripheral blood", "personalized medicine", "personalized therapeutic", "protein biomarkers", "response", "targeted treatment", "treatment strategy", "tumor" ], "approved": true } }, { "type": "Grant", "id": "13519", "attributes": { "award_id": "2141789", "title": "A Power of Place Learning Experience & Research Network to Support Community College Student Success and Civic Engagement", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Directorate for STEM Education (EDU)", "IUSE" ], "program_reference_codes": [], "program_officials": [ { "id": 692, "first_name": "Virginia", "last_name": "Carter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-01", "end_date": null, "award_amount": 599781, "principal_investigator": { "id": 29655, "first_name": "Katharine", "last_name": "Suding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 29651, "first_name": "Katharine N", "last_name": "Suding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 29652, "first_name": "Maggie", "last_name": "Prater", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 29653, "first_name": "Laura K", "last_name": "Baumgartner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 29654, "first_name": "Teresa", "last_name": "Bilinski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 172, "ror": "", "name": "University of Colorado at Boulder", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: A Power of Place Learning Experience & Research Network to Support Community College Student Success and Civic Engagement<br/><br/>The project aims to serve the national interest by facilitating undergraduate biology students’ ability and motivation to use their science skills in service of their communities with the ultimate goals of increasing public trust in science and persistence of students from populations historically underserved and underrepresented in science careers. National priorities emphasize the need for more science, technology, engineering, and math (STEM) graduates, especially those from groups historically underserved and underrepresented in STEM fields (URM students). Concurrently, there is a pressing need for college graduates, particularly STEM graduates, to have the ability and desire to use their skills in service of their communities and to increase national trust in science. Course-based undergraduate research experiences (CUREs) increase students’ persistence in STEM fields and increase their research self-efficacy and skill, especially for those from URM groups. Likewise, efforts to incorporate place-based learning through engagement in hands-on experiences that emphasize local history, culture, and service have potential to spark interest for a vast number of students and often lead to lasting civic engagement. This project leverages best practices from both CUREs and place-based learning to address the need for more URM students to persist in STEM and for more STEM graduates to serve their communities. Specifically, the project will support development and implementation of place-based CURE modules at both community colleges and four-year institutions across Colorado and New Mexico. These place-based CUREs will involve students in research that serves the local community where their institution is based. Education research for this project will seek to understand if and how place-based CUREs can increase students’ confidence and motivation to engage with their communities using their science skills and whether they increase persistence in STEM, especially for those who begin their postsecondary education at a community college. <br/><br/>This project will investigate the efficacy of a new CURE model that incorporates place-based research serving a local community as a central design feature. Project personnel will design place-based CURE modules that can be easily incorporated into introductory biology courses. These modules will be refined and revised during professional development retreats in collaboration with community college and four-year institution instructors who will then implement them with support from project personnel. The disciple-based education research associated with this project will investigate this process for students and instructors. For students, studies will investigate if CURE modules influence research self-efficacy, sense of belonging to local and scientific communities, scientific civic engagement, and intent to persist in STEM. Students who participate in courses with CURE modules will be compared to those who participate in the same courses without CURE modules or highly similar courses. Notably, this is one of the first efforts to systematically design and test CUREs that aim to involve students in community-serving research. The scientific civic engagement scale, a new psychometric measure, will be used to test whether students who participate in place-based CUREs increase their self-efficacy, knowledge, and intentions with regard to scientific civic engagement. In addition the scale will assess the level of importance they assign to engaging with a community using science skills. Data will be disaggregated to examine outcomes for various groups of students who hold URM identities. For instructors, studies will investigate the degree to which they develop self-efficacy and technical pedagogical content knowledge related to field-research based instruction. Together these results will help to elucidate the value of a) implementing place-based research in modular CUREs, and b) providing pedagogical professional development for instructors learning to implement modular CUREs. Both curricula and research results will be made publicly available for undergraduate biology instructors wishing to incorporate community-engaged science into their courses. The NSF IUSE: EHR Program supports research and development projects to improve the effectiveness of STEM education for all students. Through the Engaged Student Learning track, the program supports the creation, exploration, and implementation of promising practices and tools.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "3248", "attributes": { "award_id": "1755348", "title": "A portal into the brain: olfactory crypt neurons modulate brain viral immunity in teleost", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "Modulation" ], "program_reference_codes": [], "program_officials": [ { "id": 10224, "first_name": "Colin", "last_name": "Saldanha", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-07-01", "end_date": "2021-10-31", "award_amount": 549993, "principal_investigator": { "id": 10226, "first_name": "Irene", "last_name": "Salinas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 170, "ror": "https://ror.org/05fs6jp91", "name": "University of New Mexico", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 10225, "first_name": "Mar", "last_name": "Huertas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 170, "ror": "https://ror.org/05fs6jp91", "name": "University of New Mexico", "address": "", "city": "", "state": "NM", "zip": "", "country": "United States", "approved": true }, "abstract": "The interactions between the nervous system and the immune system determine the interactions between animals and their environment and, therefore, the survival and success of any animal species. Previous work has demonstrated that neurons can regulate immune responses, and that if neurons are infected with pathogens, they will also mount their own immune responses. The central idea of this project is that, given their direct exposure to external microorganisms, olfactory sensory neurons are able to sense infection and initiate immune responses in very rapid ways, by using electrical signals. The work focuses on one type of olfactory sensory neuron, the crypt neuron, which is unique to fishes. The hypothesis being tested is that by expressing a tyrosine kinase receptor, crypt neurons interact with proteins present in fish viruses. This interaction results in neuronal electrical signals that travel fast to the olfactory bulb in the central nervous system of the fish. Consequently, very fast (within minutes) antiviral immune responses are mounted in the nasal epithelium via cells that migrate from the olfactory bulb to the nose. The work has broad implications, including for society, because it will reveal a new mechanism by which bony fish recognize external microbial signals in the water. Understanding of this mechanism has impacts in the field of fish biology and conservation as well as aquaculture and nasal vaccine development for fish. Additional broader impacts of this project include outreach to rural schools in New Mexico and workshops to broaden participation of women in STEM disciplines.\n\nOlfactory organs detect environmental chemical signals and send them to the central nervous system (CNS) via the olfactory bulb. At the same time, olfactory sensory neurons (OSNs) are in direct contact with microorganisms present in the environment including viruses. Teleost fish have olfactory organs that resemble those of mammals, yet they have a unique type of OSN named crypt neurons. Crypt neurons express only one type of olfactory receptor, ORA4, and the tyrosine kinase receptor TrkA. Although the function of this unique OSN subset has attracted the attention of many investigators, crypt cell function remains a mystery. The goal of this project is to test a new function for crypt neurons in teleost fish. The central hypothesis is that crypt neurons detect viruses in the environment via the TrkA receptor and oversee immune responses in the CNS to avoid inflammation-induced damage. This hypothesis is being tested in rainbow trout (Oncorhynchus mykiss) crypt neurons exposed to the salmonid virus infectious hematopoietic necrosis virus (IHNV). The investigators use their pre-established trout in vivo model and pharmacological and molecular approaches to determine how crypt neurons modulate CNS innate immune responses, as well as how TrkA-viral interactions play a role in this process. Additionally, electrophysiological approaches and nerve sectioning serve to shed light on the mechanisms by which the cross-talk between the olfactory organ and the olfactory bulb occurs. The findings will elucidate an important but overlooked neuroimmune interaction in teleosts by which CNS immune responses are orchestrated from the periphery via OSN electrical signals.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9124", "attributes": { "award_id": "3R41EB029284-01S1", "title": "A PORTABLE MULTI-MODAL OPTICO-IMPEDANCE SYTEM FOR EARLY WARNING OF PROGRESSION IN STABLE COVID-19 PATIENTS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-01", "end_date": "2022-01-31", "award_amount": 155282, "principal_investigator": { "id": 24907, "first_name": "Ryan Joseph", "last_name": "Halter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1798, "ror": "", "name": "MULTIVARIATE SYSTEMS, INC.", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1798, "ror": "", "name": "MULTIVARIATE SYSTEMS, INC.", "address": "", "city": "", "state": "NH", "zip": "", "country": "United States", "approved": true }, "abstract": "/ Abstract: COVID-19, the clinical presentation associated with SARS-CoV-2 infection, has already profoundly impacted healthcare systems globally. Of particular note, communities such as long-term care facilities, assisted living communities, and prisons, are being devastated because of their high density of vulnerable individuals. Nursing home residents, which represent only 0.5% of the US population, account for 25% of COVID-19 deaths. Early detection of COVID-19 progression in these patients is critical to improving outcomes of patients who are in an early stable condition but at risk of deteriorating, but must be balanced with efficient use of primary care resources and adequate protection of healthcare workers. An early alert to progression with a high sensitivity and an acceptable rate of false-negatives would save patient lives, reduce exposure of healthcare workers, and would also facilitate resource-shifting in the face of a surge. The time, money and effort saved by allowing medical resources to be applied more accurately is the essence of precision medicine. During our current STTR efforts, we have developed and evaluated an opto-impedance system capable of integrating and classifying optical, electrical impedance spectroscopy and tomography data to detect change from baseline signatures of early ongoing hemorrhage with high accuracy. This proposal will (1) scale up our hardware inventory, (2) deploy on COVID-positive patients to collect continuous multiplex data and (3) retrain our algorithms using the data to detect associated deterioration due to progression of COVID symptoms. This multivariate approach that has already been demonstrated in other pre-shock models, has the potential to provide critical diagnostic and prognostic feedback in high-risk individuals.", "keywords": [ "Accident and Emergency department", "Address", "Algorithms", "Animals", "Assisted Living Facilities", "Blood Volume", "COVID-19", "COVID-19 detection", "COVID-19 diagnosis", "COVID-19 early detection", "COVID-19 mortality", "COVID-19 patient", "Cardiac Output", "Cardiovascular system", "Chest", "Clinic", "Clinical", "Clinical Trials", "Communities", "Complex", "Computer software", "Data", "Data Discovery", "Data Set", "Detection", "Deterioration", "Development", "Device or Instrument Development", "Devices", "Diagnosis", "Diagnostic", "Diagnostic tests", "Disease", "Drops", "Equipment and supply inventories", "Evaluation", "Extravascular Lung Water", "Family suidae", "Feedback", "Fluid Balance", "Funding", "Goals", "Health", "Health Personnel", "Health care facility", "Healthcare", "Healthcare Systems", "Hemorrhage", "Hospitalization", "Hospitals", "Individual", "Instruction", "Learning", "Legal patent", "Long-Term Care", "Lower Body Negative Pressure", "Lung", "Measurement", "Medical", "Modeling", "Monitor", "Morbidity - disease rate", "Nursing Homes", "Optics", "Outpatients", "Oxygen", "Parents", "Patient Monitoring", "Patient-Focused Outcomes", "Patients", "Peripheral", "Phase", "Population", "Preparation", "Primary Health Care", "Prisons", "Pulse Oximetry", "Resources", "Respiratory System", "Risk", "SARS-CoV-2 infection", "Shock", "Small Business Technology Transfer Research", "Spectrum Analysis", "Symptoms", "System", "Systemic disease", "Technology", "Time", "Water", "acute care", "algorithm development", "cohort", "college", "commercialization", "community living", "coronavirus disease", "cost", "density", "electric impedance", "electrical impedance tomography", "high risk", "human study", "human subject", "improved outcome", "light weight", "lung volume", "mortality", "multimodality", "non-invasive monitor", "pandemic disease", "portability", "precision medicine", "prognostic", "programs", "prototype", "response", "scale up", "sensor", "tissue oxygenation", "tomography", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "12373", "attributes": { "award_id": "1UH2AG083289-01", "title": "A Population-Based Latinx Community Study of Alzheimer’s Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20528, "first_name": "FRANK", "last_name": "Bandiera", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-15", "end_date": "2025-08-31", "award_amount": 553354, "principal_investigator": { "id": 28309, "first_name": "Kristin R", "last_name": "Krueger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 23180, "first_name": "Kumar B.", "last_name": "Rajan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 804, "ror": "https://ror.org/01j7c0b24", "name": "Rush University Medical Center", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Older Latinx adults in the US are at a greater risk of developing Alzheimer's disease (AD) and related dementias (ADRD). They exhibit a faster cognitive decline than non-Hispanic whites. However, they remain vastly underrepresented in research studies to characterize risk factors associated with progressive cognitive decline. A better understanding of risk factors can provide better treatment and design appropriate preventive strategies for older Latinx adults. Since older Latinx adults have a higher prevalence of cardiovascular risk factors, their risk of developing ADRD is high in old age. Older Latinx communities were disproportionately affected by the COVID-19 pandemic, which can increase their risk for neurological disorders. This UH2/UH3 cooperative agreement aims to engage and develop the infrastructure for a new Latinx cohort study with the following aims: (1) build infrastructure, community outreach, and the external advisory board for a new Latinx cohort; (2) develop ongoing engagement with the community and resource sharing plan; (3) collect data on 250 Latinx participants from East Side sampling frame; and (4) test the exploratory hypotheses that Latinx participants have a higher prevalence of clinically diagnosed AD and MCI, and the impact of COVID-19 on AD is more severe compared to non-Hispanic whites, and the ApoE4 association with clinical AD and MCI is the same as NHW. The long-term objective is to perform a sizeable muti-ethnic study, combining the Latinx cohort with our existing Chicago Health and Aging Project (CHAP), a population-based community study in four neighborhoods with 10,801 participants with 63% non-Hispanic Black and 37% non-Hispanic white participants. This UH2/UH3 proposal will add a new Latinx cohort in the East Side community of Chicago, with over 60% Latinx. A multi-ethnic cohort will allow us to test several biological and psychosocial hypotheses of high public health significance. The collection of biospecimens will also allow for testing further blood biomarker hypotheses, developing an omics pipeline down the road, and providing additional infrastructure for pathology studies in a population-based cohort study with minorities.", "keywords": [ "Address", "Adult", "Aging", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease diagnosis", "Alzheimer&apos", "s disease related dementia", "Behavioral", "Biological", "Biological Markers", "Black race", "Blood", "Blood specimen", "COVID-19", "COVID-19 impact", "COVID-19 outbreak", "COVID-19 pandemic effects", "Censuses", "Chicago", "Clinical", "Cohort Studies", "Collection", "Communities", "Community Outreach", "Data", "Data Collection", "Death Rate", "Dementia", "Elderly", "Epidemic", "Ethnic Origin", "Ethnic Population", "Event", "Exhibits", "Focus Groups", "Future", "Genetic", "Goals", "Grant", "Growth", "Health", "Health system", "Height", "High Prevalence", "Hispanic", "Hispanic Populations", "Household", "Impaired cognition", "Incidence", "Individual", "Infrastructure", "Knowledge", "Latinx", "Latinx population", "Life Style", "Minority", "Minority Groups", "Neighborhoods", "Not Hispanic or Latino", "Participant", "Pathology", "Perception", "Persons", "Phase", "Population", "Population Study", "Prevalence", "Prevention strategy", "Procedures", "Protocols documentation", "Public Health", "Race", "Recommendation", "Research", "Research Infrastructure", "Research Project Grants", "Resource Sharing", "Resources", "Risk", "Risk Factors", "Sampling", "Side", "Testing", "U-Series Cooperative Agreements", "United States National Institutes of Health", "Update", "Washington", "apolipoprotein E-4", "biracial", "cardiovascular risk factor", "clinical diagnosis", "cognitive function", "cognitive testing", "cohort", "community organizations", "design", "experience", "health determinants", "health inequalities", "human old age (65+)", "improved", "infection rate", "member", "mild cognitive impairment", "minority health", "minority health disparity", "multi-ethnic", "nervous system disorder", "novel", "population based", "population health", "psychologic", "psychosocial", "racial difference", "racial population", "recruit", "research study", "social", "social determinants", "success", "tool", "web site" ], "approved": true } }, { "type": "Grant", "id": "10539", "attributes": { "award_id": "1U01EB033305-01", "title": "A point-of-care device using Single Molecule Array (Simoa) to measure viral antigens in nasal swabs, saliva, and blood", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 6433, "first_name": "Tiffani Bailey", "last_name": "Lash", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-22", "end_date": "2025-08-31", "award_amount": 1705157, "principal_investigator": { "id": 26550, "first_name": "David C", "last_name": "Duffy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26551, "first_name": "Nira", "last_name": "Pollock", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1940, "ror": "", "name": "QUANTERIX CORPORATION", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this project is to develop a simple-to-use, low-cost, and small instrument and associated consumable for point-of-care (POC) diagnoses based on the ultrasensitive detection of proteins. The proposed system will combine detection of proteins using the Single Molecule Array (Simoa; Quanterix Corporation) technology and assay processing using digital microfluidics (DMF) to enable POC immunoassays with the sensitivity and specificity of nucleic acid amplification tests without the need for nucleic acid purification or amplification, and with the simplicity, sample type flexibility, and diagnostic performance to deliver central lab diagnostic quality in POC settings. The proposed system would be composed of a sample- to-answer, random access, benchtop instrument utilizing a universal consumable design accepting a broad range of minimally processed samples relevant to POC diagnosis of disease, including swab, saliva, and blood (including fingerstick) samples. We will first apply this technology to the diagnosis of COVID-19 and influenza, optimizing existing assays for SARS-CoV-2 N-protein and developing new multiplexed assays for influenza A and B antigens, along with simple sample preparation methods, for testing of nasal/nasopharyngeal (NP) swab (SARS-CoV-2/influenza) and saliva/blood (SARS-CoV-2 only) samples. This project—a collaboration between Quanterix (Dr. Duffy, co-PI), Boston Children's Hospital (Dr. Pollock, co-PI), and University of Toronto (Dr. Wheeler, co-investigator)—has four specific aims to achieve these goals. First, we will develop the key technologies to enable the POC system, namely: a low-cost Simoa imager with a small form factor; single molecule labels that do not require sealing in microwell arrays; and, the DMF building blocks for assay processing, resulting in an integrated Simoa-DMF device. Second, we will design, develop, and test Simoa POC instruments and consumables, first in prototype and then for test validation. Third, we will optimize/develop and validate analytically Simoa assays (including sample preparation options) for SARS- CoV-2 (nasal swab, saliva, blood) and multiplex influenza A/B (NP swab) antigens, and test them on the prototype Simoa POC system. Finally, we will clinically validate the POC antigen tests against gold-standard molecular tests for all sample types using discarded/banked clinical samples, and evaluate performance of the POC system in POC settings using contrived clinical samples. User feedback will inform development throughout the proposal. The long-term objective of this research is to develop a broadly enabling technology that would allow the diagnosis of diseases using ultrasensitive protein detection at the POC in a small, low-cost benchtop system. This type of capability is available for molecular testing but not for protein detection, and would combine high sensitivity with low cost and an alternative supply chain to support diagnosis of infectious diseases in diverse clinical settings. This system would be a critical new diagnostic tool ready both for routine POC diagnosis of infectious diseases and to benefit the world in the event of the next pandemic.", "keywords": [ "2019-nCoV", "Adult", "Anterior", "Antigens", "Biological Assay", "Blood", "Blood specimen", "Boston", "COVID-19", "COVID-19 assay", "COVID-19 diagnosis", "COVID-19 pandemic", "COVID-19 testing", "Child", "Childhood", "Clinical", "Collaborations", "Communicable Diseases", "Detection", "Development", "Devices", "Diagnosis", "Diagnostic", "Early Diagnosis", "Environment", "Enzyme-Linked Immunosorbent Assay", "Event", "FDA Emergency Use Authorization", "Feedback", "Goals", "Gold", "Immunoassay", "Infection", "Infection Control", "Influenza", "Influenza A virus", "Influenza B Virus", "Intervention", "Kenya", "Label", "Measurement", "Measures", "Methods", "Microfluidic Microchips", "Microfluidics", "Molecular", "Nose", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Nucleoproteins", "Outcome", "Patients", "Pediatric Hospitals", "Performance", "Point of Care Technology", "Point-of-Care Systems", "Preparation", "Price", "Process", "Proteins", "Refugee Camp", "Research", "Research Personnel", "Running", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 antigen", "Saliva", "Sampling", "Sensitivity and Specificity", "Swab", "System", "Systems Development", "Technology", "Testing", "Time", "Universities", "Validation", "Viral", "Viral Antigens", "Virus", "Virus Diseases", "antigen detection", "antigen test", "assay development", "base", "communicable disease diagnosis", "cost", "design", "diagnostic tool", "digital", "disease diagnosis", "electric field", "flexibility", "imager", "improved", "innovation", "instrument", "microfluidic technology", "miniaturized device", "multiplex assay", "nasal swab", "nasopharyngeal swab", "novel diagnostics", "nucleic acid purification", "pandemic disease", "pathogen", "point of care", "point of care testing", "point-of-care diagnosis", "point-of-care diagnostics", "price lists", "prototype", "saliva sample", "seal", "single molecule", "targeted treatment", "usability", "user-friendly", "validation studies" ], "approved": true } }, { "type": "Grant", "id": "3190", "attributes": { "award_id": "1804416", "title": "A point-of-care device for diagnosis and management of pulmonary diseases", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "BioP-Biophotonics" ], "program_reference_codes": [], "program_officials": [ { "id": 9982, "first_name": "Steve", "last_name": "Zehnder", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-05-01", "end_date": "2021-04-30", "award_amount": 325000, "principal_investigator": { "id": 9985, "first_name": "Stefan", "last_name": "Bossmann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 197, "ror": "https://ror.org/05p1j8758", "name": "Kansas State University", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 9984, "first_name": "Christopher T", "last_name": "Culbertson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 197, "ror": "https://ror.org/05p1j8758", "name": "Kansas State University", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "Lung cancer is the most common cause of cancer-related death. Symptoms, such as fever or fatigue, are unspecific while other indicators are typical of many other diseases. Development of a reliable technique that detects lung cancer at the earliest possible stage, is critical for successful outcomes. Several competing techniques demonstrated their ability to diagnose intermediate and late stage lung cancer, but failed to detect early stage cancer which significantly decreases their utility. This project will synthesize a set of novel optical biosensors and indicators that have been implicated in early stage lung cancer. The development of this novel non-invasive, cost effective, and reliable screening tool would be transformative for the whole field of lung cancer prevention.\n\nThe team will achieve technical proof-of-principle by focusing on a set of biomarkers (matrix metalloproteinases and cathepsins) that have been shown to be successful in detecting stage 1 non-small-cell lung cancer (NSCLC), the most common form of lung cancer. An integrated microfluidic device will be developed to handle a new class of nano-biosensors designed to detect a large number of enzymes. The panel of biomarkers that will be detected by the proposed device will be optimized based on samples collected from animal models first, and human patients later.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7875", "attributes": { "award_id": "1R03HD107598-01", "title": "A PILOT TRIAL OF TELEHEALTH ACTIVE VIDEO GAMING USING IMMERSIVE VIRTUAL REALITY ON CARDIOMETABOLIC HEALTH AMONG YOUTH WITH CEREBRAL PALSY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 21015, "first_name": "TOYIN DELE", "last_name": "Ajisafe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-03-01", "end_date": "2024-02-29", "award_amount": 145348, "principal_investigator": { "id": 23721, "first_name": "Byron", "last_name": "Lai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 612, "ror": "https://ror.org/008s83205", "name": "University of Alabama at Birmingham", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Byron Lai, PhD – R03 Project Summary/Abstract Due to alarmingly low rates of exercise participation, youth with cerebral palsy (YwCP) are at substantially high risk for cardiovascular disease (CVD), related conditions, and CVD mortality as they age into adulthood. Regular participation in aerobic exercise is an effective non-pharmaceutical method for preventing cardiovascular disease and metabolic syndrome, but effective modalities such as walking, running, and cycling are often not suitable for the large demographic of YwCP who have reduced mobility. The growing availability of internet access and acceptance of telehealth (due to the coronavirus pandemic) create an unprecedented opportunity to engage large, underserved groups of YwCP in exercise behavior. When combined with recent advances in consumer-available virtual reality (VR) video game technology, telehealth programs have the potential to create accessible and fully immersive single- and multiplayer active video gaming experiences at the home. This enjoyable modality of exercise may enhance the likelihood that YwCP maintain regular participation over periods of time that are necessary to elicit changes in cardiometabolic health. This application proposes a pilot project that builds upon our recent feasibility work. The intervention will utilize a theory driven protocol for remotely delivering and objectively monitoring VR exergaming through telehealth. The procedures will be purely telehealth driven and include remote screening, consent, data collection, and intervention procedures. Participants will be recruited from a children’s hospital, adult rehabilitation clinic, and network of community organizations. Thirty-four YwCP will be randomized to one of two groups: 1) 12 weeks of VR exergaming plus behavioral tele-physical education coaching (VRT) or a 2) 12-week waitlist control (WC) that undergoes habitual activity before receiving VRT. VRT participants will be prescribed to complete at least 150 min per week of moderate-intensity exercise. Using exploratory statistical procedures, this pilot study will compare changes in high sensitivity C-reactive protein and blood insulin, hemoglobin A1c, triglycerides, cholesterol and pressure between the VRT and WC only groups. At 0, 6, and 12 weeks, cardiometabolic outcomes will be measured at the home via tele-assessment. Additionally, the study will qualitatively explore behavioral mechanisms that underly participation via semi-structured interviews with participants from both groups at post-intervention or dropout. Using a Grounded Theory approach, participant feedback will be constructed into a substantive theory that can maximize long-term engagement of YwCP in tele-exergaming. Study findings will be used to inform the development of a telehealth efficacy trial that can be easily replicated across various sites and settings.", "keywords": [ "Adherence", "Adult", "Aerobic Exercise", "Age", "Analysis of Covariance", "Behavior", "Behavioral", "Behavioral Mechanisms", "Blood", "Blood Pressure", "C-reactive protein", "Cardiovascular Diseases", "Caregivers", "Case Study", "Cerebral Palsy", "Childhood", "Cholesterol", "Clinic", "Collection", "Community Networks", "Computers", "Consent", "Control Groups", "Coronavirus", "Data Collection", "Development", "Diabetes Mellitus", "Diagnostic Reagent Kits", "Doctor of Philosophy", "Dose", "Dropout", "Enrollment", "Equipment", "Evidence based program", "Exercise", "Feedback", "General Population", "Glycosylated hemoglobin A", "Guidelines", "Health", "Health Professional", "Home", "Hypertension", "Immersion", "Insulin", "Internet", "Intervention", "Interview", "Measurement", "Measures", "Metabolic syndrome", "Methods", "Modality", "Monitor", "Motion", "Motor", "Outcome", "Participant", "Pediatric Hospitals", "Persons", "Physical Education", "Pilot Projects", "Population", "Procedures", "Property", "Protocols documentation", "Psychometrics", "Randomized", "Randomized Controlled Trials", "Rehabilitation therapy", "Research", "Research Personnel", "Resolution", "Risk Factors", "Running", "Sample Size", "Site", "Spottings", "Structure", "Supervision", "Techniques", "Technology", "Time", "Triglycerides", "Underserved Population", "Video Games", "Videoconferencing", "Waiting Lists", "Walking", "Wheelchairs", "Work", "Youth", "arm", "base", "cardiometabolic risk", "cardiometabolism", "cardiovascular disorder risk", "cohort", "community organizations", "cost", "cost efficient", "design", "disability", "eHealth", "efficacy study", "efficacy trial", "exercise intensity", "exercise intervention", "exercise training", "exergame", "experience", "head mounted display", "high risk", "hypercholesterolemia", "improved", "mode of exercise", "mortality", "pandemic disease", "physically handicapped", "pilot trial", "post intervention", "pressure", "prevent", "programs", "recruit", "remote delivery", "remote screening", "scale up", "sedentary lifestyle", "statistics", "telehealth", "telemonitoring", "theories", "vigorous intensity", "virtual monitoring", "virtual reality", "virtual reality environment" ], "approved": true } }, { "type": "Grant", "id": "15819", "attributes": { "award_id": "1R21CA303350-01", "title": "A Pilot Study to Correlate 4-[18F]fluoro-1-naphthol PET/CT Imaging with Chronic Graft Versus Host Disease Manifestations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44227, "first_name": "YISONG", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-08", "end_date": "2027-08-31", "award_amount": 358605, "principal_investigator": { "id": 44228, "first_name": "George Liwei", "last_name": "Chen", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44229, "first_name": "David", "last_name": "Piwnica-Worms", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1420, "ror": "", "name": "UNIVERSITY OF TX MD ANDERSON CAN CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "/ PROJECT SUMMARY Allogeneic hematopoietic cell transplant (alloHCT) is a curative therapy for many life-threatening hematologic malignancies but its full therapeutic potential is undermined by complications such as chronic graft-versus-host disease (GVHD). Chronic GVHD is the greatest cause of non- relapse mortality and develops in 25-50% of long-term survivors of alloHCT. Novel approaches are needed to diagnose and treat chronic GVHD after alloHCT. 4-[18F]fluoro-1-naphthol ([18F]4FN) is a novel radiotracer that is specific to high energy reactive oxygen and nitrogen species produced during the respiratory burst in the active innate immune system. The proposed pilot study will apply [18F]4FN PET/CT to 16 patients with joint and other manifestations of chronic GVHD to obtain preliminary estimates of the anatomic and temporal correlations between [18F]4FN PET/CT signal intensity / location and chronic GVHD manifestations. Although PET, CT, and MRI have previously been used to image chronic GVHD, our approach differs by the use of [18F]4FN which reflects the functional activity of the innate immunity as indicated by respiratory burst intensity in contrast to glucose uptake as in [18F]fluoro-2-deoxyglucose (FDG) PET or anatomical changes as in CT and MRI. Patients will receive one to three [18F]4FN PET/CT scans and six to twelve Chronic GVHD Assessments. Data from these endpoints will be used to calculate preliminary estimates of the utility of [18F]4FN PET/CT as a predictive and prognostic / pharmacodynamic biomarker. We will test the following hypotheses with our specific aims: 1) [18F]4FN PET/CT images correlate anatomically with chronic GVHD manifestations and selected [18F]4FN PET/CT images will precede chronic GVHD manifestation changes. 2) [18F]4FN PET/CT images will provide pharmacodynamic metrics for treatment of chronic GVHD. Information gained from this pilot study will form the scientific basis for a subsequent larger phase II imaging trial to evaluate [18F]4FN PET/CT as a quantitative, predictive, and prognostic / pharmacodynamic biomarker for chronic GVHD. [18F]4FN PET/CT could be applied to other inflammatory conditions such as acute GVHD and cytokine release syndrome / immune effector cell associated neurotoxicity syndrome after CAR T cell infusion, and rheumatologic diseases. This multiple principal investigator project combines the unique, complementary expertise of Drs. Chen (alloHCT, chronic GVHD) and Piwnica-Worms (molecular imaging, radiopharmaceuticals). In 2022-2023, MD Anderson Cancer Center performed 416 adult alloHCTs of which 13.5% developed chronic GVHD within 1 year.", "keywords": [ "Acute Graft Versus Host Disease", "Adult", "Affect", "Allogenic", "Anatomy", "Biological Markers", "Cancer Center", "Cause of Death", "Clinical", "Clinical Trials", "Connective Tissue", "Consensus Development", "Data", "Deoxyglucose", "Development", "Diagnosis", "Disease", "Disparate", "Early Diagnosis", "Elasticity", "Evaluation", "Feasibility Studies", "Fibrosis", "Functional impairment", "Goals", "Hematologic Neoplasms", "Hematopoietic Neoplasms", "Hematopoietic Stem Cell Transplantation", "Image", "Immune System Diseases", "Immune system", "Inflammation", "Inflammatory", "Infusion procedures", "Innate Immune System", "Interobserver Variability", "Intervention Studies", "Intervention Trial", "Investigation", "Joints", "Lesion", "Life", "Location", "Long-Term Survivors", "Macrophage", "Magnetic Resonance Imaging", "Measurement", "Measures", "Methods", "Modality", "Naphthols", "Natural Immunity", "Nitrogen", "Organ", "Oxygen", "PET positivity", "Pain", "Patient-Focused Outcomes", "Patients", "Pharmacodynamics", "Phase", "Phase Ia Trial", "Physical Examination", "Pilot Projects", "Positron-Emission Tomography", "Prediction of Response to Therapy", "Principal Investigator", "Radiopharmaceuticals", "Reaction", "Reporting", "Research", "Respiratory Burst", "Rheumatism", "Risk", "Safety", "Scanning", "Severities", "Signal Transduction", "Skin", "Skin Tissue", "Symptoms", "Testing", "Therapeutic", "Therapeutic Agents", "Tissues", "Transplant Recipients", "United States National Institutes of Health", "X-Ray Computed Tomography", "arthropathies", "chimeric antigen receptor T cells", "chronic graft versus host disease", "clinical imaging", "clinical phenotype", "curative treatments", "cytokine release syndrome", "design", "effective therapy", "functional status", "glucose uptake", "immune effector cell-associated neurotoxicity syndrome", "improved", "leukemia/lymphoma", "molecular imaging", "mortality", "novel", "novel strategies", "novel therapeutics", "pharmacodynamic biomarker", "physical symptom", "predicting response", "predictive marker", "prognostic", "radiotracer", "response", "spatiotemporal", "therapy development", "treatment response" ], "approved": true } }, { "type": "Grant", "id": "10585", "attributes": { "award_id": "1R21MD017662-01", "title": "A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 7440, "first_name": "DOROTHY M", "last_name": "CASTILLE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-23", "end_date": "2024-05-31", "award_amount": 255563, "principal_investigator": { "id": 26610, "first_name": "GEORGE L", "last_name": "KING", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1642, "ror": "https://ror.org/0280a3n32", "name": "Joslin Diabetes Center", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Rates of Type 2 Diabetes (T2D) are increasing both nationally and globally. In addition to known T2D complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease, T2D is known to affect cognitive impairment and even severity of COVID-19 infection. A few studies have shown the benefit of Continuous Glucose Monitoring (CGM) devices for better glycemic management in T2D populations. While prevention and management protocols for T2D are ubiquitous, there continue to exist large racial/ethnic disparities amongst the general US population. Asian Americans (AA), specifically Chinese-Americans, present with much higher T2D prevalence and face disparities in T2D care for the following reasons: 1) Stigma arising from the “model minority myth”, exacerbated by the rise in anti-Asian sentiments during the COVID-19 pandemic; 2) Higher T2D unawareness rate; 3) Cultural and language barriers including limited digital literacy and English proficiency; and 4) Historical exclusion from T2D studies, including those on CGM devices and T2D, in which culturally-relevant facilitators and barriers to CGM use have yet to be evaluated in AAs. This study will specifically examine how T2D could be better managed in Chinese Americans through a CGM intervention, as compared to standard fingerstick glucose monitoring (FSGM). We will be conducting a 6- month, single-site, open-labeled randomized controlled trial examining CGM versus no CGM (FSGM) use in 1st-generation Chinese Americans. Our specific aims are: Sp. Aim 1: In a pilot 6-month randomized clinical trial, we will examine the impact of CGM use vs. No CGM among 1st generation Chinese Americans with T2D. Sub-Aim 1.1. Evaluate feasibility (adherence and consistency) and quality of life measures during CGM use in this population. Sub-Aim 1.2. Generate precision estimates of the distribution of the secondary outcomes (6- month glycemic control and lipid markers) in both arms to inform a future randomized clinical trial (RCT). Sp. Aim 2: Identify multi-level barriers and facilitators of CGM use for Chinese Americans with T2D, using a socioecological framework (patient-level, provider-level, and community/environment level). We will evaluate the implementation process (facilitators and impediments), resource requirements, and intermediate patient adherence outcomes for the program using mixed-methods approaches. These will inform design of culturally- tailored intervention for a larger randomized controlled trial.", "keywords": [ "Address", "Adherence", "Advocacy", "Affect", "Age", "Asian", "Asian Americans", "Body mass index", "COVID-19 pandemic", "COVID-19 severity", "Cardiovascular Diseases", "Caring", "China", "Chinese", "Chinese American", "Clinical Trials", "Communities", "Complications of Diabetes Mellitus", "Data", "Diabetes Mellitus", "Diagnosis", "East Asian", "Education", "Environment", "Ethnic group", "Exclusion", "Face", "Future", "Generations", "Guidelines", "Health", "Health Technology", "Healthcare", "Immigrant", "Impaired cognition", "Intervention", "Japanese", "Kidney Diseases", "Koreans", "Language", "Limited English Proficiency", "Link", "Lipids", "Measures", "Medicaid", "Medicare", "Metabolic", "Methods", "Minority", "Modeling", "National Health and Nutrition Examination Survey", "Neuropathy", "Non-Insulin-Dependent Diabetes Mellitus", "Not Hispanic or Latino", "Outcome", "Participant", "Patients", "Population", "Prevalence", "Prevention", "Protocols documentation", "Provider", "Quality of life", "Race", "Randomized Clinical Trials", "Randomized Controlled Trials", "Reporting", "Resources", "Retinal Diseases", "SARS-CoV-2 infection", "Site", "South Asian", "Subgroup", "Technology", "Uninsured", "Variant", "arm", "compliance behavior", "cost", "design", "diabetes risk", "digital", "ethnic minority", "glucose monitor", "glycemic control", "health care disparity", "implementation evaluation", "implementation process", "implementation strategy", "innovation", "literacy", "monitoring device", "open label", "pandemic disease", "policy implication", "programs", "racial and ethnic disparities", "secondary outcome", "sex", "skills", "social health determinants", "social stigma", "southeast Asian", "tool", "vocalization" ], "approved": true } } ], "meta": { "pagination": { "page": 1385, "pages": 1424, "count": 14236 } } }